Global phase III trial of BOW050 [adalimumab biosimilar] in patients with autoimmune disorders

Trial Profile

Global phase III trial of BOW050 [adalimumab biosimilar] in patients with autoimmune disorders

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Mar 2016 According to an Epirus media release, global regulatory filing for BOW-050 is expected in 2018.
    • 11 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top